Tier 2 — strong

N-acetylcysteine prevents glutathione decrease and does not interfere with paracetamol antinociceptive effect at therapeutic dosage: a randomized double-blind controlled trial in healthy subjects

Gisèle Pickering, Nicolas Macian, Isabelle Papet, Christian Dualé, Catherine Coudert, Bruno Pereira
Fundam Clin Pharmacol 2019 33(3):303-311

Bibliography

PubMed
PMID 30471141
DOI
10.1111/fcp.12437
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized controlled human study
ModelHuman
Sample24 healthy volunteers
InterventionTherapeutic-dose paracetamol for 4 days with or without NAC
Duration4 days
EndpointsGlutathione; Oxidative stress markers; Antinociceptive response

What the study showed, in plain terms

Healthy-volunteer trial testing whether NAC preserves glutathione during repeated therapeutic paracetamol exposure.

Key findings

NAC prevented a fall in glutathione without eliminating the measured analgesic effect of therapeutic paracetamol.

What this study can and cannot tell us

Small healthy-volunteer study over four days; not an overdose-treatment trial.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology